These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24468754)

  • 21. Bone benefits of testosterone replacement therapy in male hypogonadism.
    Tirabassi G; Biagioli A; Balercia G
    Panminerva Med; 2014 Jun; 56(2):151-63. PubMed ID: 24994579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoporosis in men: update 2011.
    Orwig DL; Chiles N; Jones M; Hochberg MC
    Rheum Dis Clin North Am; 2011 Aug; 37(3):401-14, vi. PubMed ID: 22023899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing bone complications in prostate cancer.
    Bishr M; Saad F
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
    Schmitz-Dräger BJ; Weiss C; Ebert T; Dörsam J; Bismarck E
    Urol Int; 2013; 90(3):329-33. PubMed ID: 23407093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintaining bone health in prostate cancer throughout the disease continuum.
    Saad F; Eastham J
    Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
    Iolascon G; Resmini G; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.
    Brown JE; Ellis SP; Silcocks P; Blumsohn A; Gutcher SA; Radstone C; Hancock BW; Hatton MQ; Coleman RE
    Clin Cancer Res; 2006 Nov; 12(21):6480-6. PubMed ID: 17085662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Testosterone and bone: indications and limitations].
    Stoll D; Puder JJ; Lamy O
    Rev Med Suisse; 2011 Jun; 7(299):1311-5. PubMed ID: 21793421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment.
    De Rosa M; Paesano L; Nuzzo V; Zarrilli S; Del Puente A; Oriente P; Lupoli G
    J Endocrinol Invest; 2001 Apr; 24(4):246-52. PubMed ID: 11383911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men.
    Pezzaioli LC; Porcelli T; Delbarba A; Maffezzoni F; Focà E; Castelli F; Cappelli C; Ferlin A; Quiros-Roldan ME
    J Endocrinol Invest; 2022 Feb; 45(2):433-443. PubMed ID: 34460073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.
    Leifke E; Körner HC; Link TM; Behre HM; Peters PE; Nieschlag E
    Eur J Endocrinol; 1998 Jan; 138(1):51-8. PubMed ID: 9461316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Gioia A; Biagioli A; Lenzi A; Balercia G
    J Endocrinol Invest; 2014 Apr; 37(4):393-400. PubMed ID: 24458833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Bisphosphonates on Bone of Osteoporotic Men With Different Androgen Levels: A Case-Control Study.
    Zhou BN; Hu J; Sun L; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Endocr Pract; 2022 Mar; 28(3):250-256. PubMed ID: 34968764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoporosis, bone turnover and hypogonadism in elderly men with treated leprosy.
    Ishikawa A; Ishikawa S; Hirakawa M
    Lepr Rev; 2001 Sep; 72(3):322-9. PubMed ID: 11715278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.
    Higano CS
    Urol Oncol; 2003; 21(5):392-8. PubMed ID: 14670551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management.
    Ebeling PR
    Drugs Aging; 1998 Dec; 13(6):421-34. PubMed ID: 9883398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.